Recombinant Human Acid Sphingomyelinase as an Adjuvant to Sorafenib Treatment of Experimental Liver Cancer

BACKGROUND: Hepatocellular carcinoma (HCC) is the most common form of liver cancer and the third leading cause of cancer death worldwide. The only approved systemic treatment for unresectable HCC is the oral kinase inhibitor, sorafenib. Recombinant human acid sphingomyelinase (rhASM), which hydrolyz...

Descripción completa

Detalles Bibliográficos
Autores principales: Savić, Radoslav, He, Xingxuan, Fiel, Isabel, Schuchman, Edward H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3665770/
https://www.ncbi.nlm.nih.gov/pubmed/23724146
http://dx.doi.org/10.1371/journal.pone.0065620

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3665770/
https://www.ncbi.nlm.nih.gov/pubmed/23724146
http://dx.doi.org/10.1371/journal.pone.0065620

Ejemplares similares